New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:08 EDTALR, RHHBY, DHR, ABTAlere CEO departure sharpens focus on potential acquisition, says JMP Securities
After the CEO of Alere, Ron Zwanziger, resigned, JMP Securities thinks the resignation "brings the notion of Alere's potential acquisition front and center." The firm sees Alere as "a natural fit" for Roche (RHHBY), Abbott (ABT), or Danaher (DHR).
News For ALR;RHHBY;DHR;ABT From The Last 14 Days
Check below for free stories on ALR;RHHBY;DHR;ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 16, 2014
11:23 EDTDHRDanaher says "very busy" on M&A front
says "very, very busy" on M&A side. Sees ability to get deals done. Says July, August, "a little better than we thought" in U.S., Europe "okay." Says has a "little bit" of exposure to Russia, "hurting us a little bit" right now. Comments made at the Morgan Stanley Laguna Conference.
08:54 EDTALRAlere CEO takeover attempt lacks financing details, says Raymond James
Subscribe for More Information
07:31 EDTALR, RHHBYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:18 EDTALRAlere worth $45-$50 to strategic buyer, says Canaccord
Canaccord noted the former Chairman and CEO of Alere revealed a proposed buyout of $46 per share. The firm feels the filing indicates genuine interest and believes the company may be worth $45-$50 to a strategic buyer. Canaccord raised its price target to $46 to match the offer and reiterates its Buy rating on the shares.
September 15, 2014
19:32 EDTALRAlere responds to letter from former executives
Subscribe for More Information
12:31 EDTALROn The Fly: Midday Wrap
Subscribe for More Information
09:32 EDTABTAbbott initiates ABSORB IV trial
Abbott announced the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold is more cost-effective and offers a higher quality of life than a permanent, metallic drug eluting stent. Unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3K people with coronary artery disease, mostly in the U.S. The ABSORB IV trial is designed to confirm these novel findings that treatment with the Absorb device can help provide people with heart disease a higher quality of life after a heart stent procedure. The data from the ABSORB IV trial will be combined with the data from the ABSORB III trial to create a population of more than 5K people studied in the U.S. This data set, which is the largest of its kind for bioresorbable heart devices, provides an opportunity to evaluate the performance of Absorb compared to the current standard of a metallic drug eluting stent across a number of measures, including the broader health economic impact of this innovative therapy.
09:15 EDTALRRon Zwanziger plans to offer $46 per share to aquire Alere
Subscribe for More Information
08:56 EDTDHRDanaher: It's important not to read too much into 2 deals for company direction
Subscribe for More Information
08:49 EDTDHRDanaher expects global dentistry market to grow 3%-5%
Subscribe for More Information
08:47 EDTDHRDanaher expects Nobel Biocare acquisition to be accretive to EPS by 5c in 2015
Subscribe for More Information
07:45 EDTABTCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:42 EDTDHRMorgan Stanley to hold a conference
Subscribe for More Information
05:58 EDTDHRDanaher to host conference call
Subscribe for More Information
05:20 EDTDHRDanaher to acquire Nobel Biocare Holding for CHF 17.10 per share
Danaher has entered into a definitive transaction agreement with Nobel Biocare Holding AG pursuant to which Danaher or one of its direct or indirect subsidiaries will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2B. The deal is expected to widen Danaher's market presence in the global dental industry and allow Nobel Biocare to accelerate its strategic objectives and future growth. Under the terms of the transaction agreement, Danaher will commence a voluntary all-cash public tender offer of CHF 17.10 per Nobel Biocare share to purchase all of Nobel Biocare's publicly held registered shares. The pre-announcement of the public tender offer is published today. The offer prospectus is expected to be published on or around October 1 and the offer period during which Nobel Biocare shareholders may tender their registered shares is expected to start on or around October 16. In 2013, Nobel Biocare generated annual revenues of approximately $750M. Nobel Biocare would become part of Danaher's $2.2B Dental segment and complements Danaher's position in the implant industry. The Nobel Biocare board has recommended that Nobel Biocare shareholders accept and tender their shares into the offer, which represents a premium of approximately 23% to Nobel Biocare's closing price on July 28, the day before market speculation began regarding a potential sale of the company, or 28% on the basis of the 60 day volume-weighted average price on that date. The offer is expected to be completed in late 2014 or early 2015.
05:17 EDTDHRDanaher to acquire Nobel Biocare Holding for CHF 17.10 per share
Subscribe for More Information
September 14, 2014
13:30 EDTABTAbbott announces positive one-year clinical results from ABSORB II
Subscribe for More Information
September 11, 2014
13:41 EDTABTAbbott announces new $3B share repurchase program
Subscribe for More Information
September 10, 2014
13:04 EDTRHHBYRoche unit receives orphan status for lung cancer mutation drug
Subscribe for More Information
September 9, 2014
06:42 EDTABTLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use